Sugi Predict

Sugi Predict / Compounds / SCHEMBL2432630

SCHEMBL2432630

SCHEMBL2432630

Nc1nc(-c2ccccc2)c(Cl)s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.63
▸ MAPT P10636 9/20 0.63
▸ CYP1A2 P05177 3/20 0.63
▸ CYP2D6 P10635 2/20 0.63
▸ CYP2C19 P33261 2/20 0.63
▸ KDM4E B2RXH2 2/20 0.56
▸ GAA P10253 2/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ LMNA P02545 5/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ GLA P06280 1/20 0.53
▸ MEN1 O00255 7/20 0.53
▸ KMT2A Q03164 7/20 0.53
▸ MAPK1 P28482 5/20 0.53
▸ TDP1 Q9NUW8 4/20 0.53
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ HTT P42858 2/20 0.53
▸ MMP14 P50281 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9727980 0.80 TGFBR1 (0.51) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL23610341 0.80 ALDH1A1 (0.50) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL543685 0.79 ALDH1A1 (0.68) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL9040810 0.79 ALDH1A1 (0.50) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL234287 0.78 ALDH1A1 (1.00) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL10120712 0.77 ALDH1A1 (0.80) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL4037398 0.77 MYC (0.50) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL19638014 0.77 MYC (0.57) ALDH1A1MAPTCYP1A2CYP2C19KDM4E
SCHEMBL2175865 0.76 ALDH1A1 (0.63) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL7076758 0.76 ALDH1A1 (0.63) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 — — US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 — — US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 — — US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 — — US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 — — EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 — — EP disclosed
CN-107207445-B Adenosine A3Modulators of receptors 帕罗生物制药有限公司 2021-03-16 — — CN disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 — — CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 — — WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 — — WO disclosed
EP-3248964-B1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA SL (ES) 2019-07-17 — — EP disclosed
US-10238637-B2 Modulators of the adenosine A3 receptors PALOBIOFARMA, S.L. (ES) 2019-03-26 — — US disclosed
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS PALOBIOFARMA, S.L. (ES) 2018-09-20 — — US disclosed
EP-3248964-A1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA S.L. (ES) 2017-11-29 — — EP disclosed
CN-107207445-A Adenosine A3The conditioning agent of acceptor 帕罗生物制药有限公司 2017-09-26 — — CN disclosed
EP-2366698-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor Galapagos SAS (FR) 2011-09-21 — — EP disclosed
EP-2366698-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor Galapagos SAS (FR) 2011-09-21 — — EP disclosed
EP-2041103-A2 DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR Galapagos SAS (FR) 2009-04-01 — — EP disclosed
US-20080125424-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor GALAPAGOS SAS (FR) 2008-05-29 — — US disclosed
WO-2008006625-A2 DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR GALAPAGOS SAS (FR) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 ALDH1A1 2267/4885MAPT 706/4885CYP1A2 4393/4885
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS ADORA3, ADORA2A, ADORA1 ALDH1A1 483/4885MAPT 3832/4885CYP1A2 1065/4885
US-20080125424-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor UTS2R, CASR, GPR17 ALDH1A1 785/4885MAPT 1435/4885CYP1A2 3385/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 ALDH1A1 2267/4885MAPT 706/4885CYP1A2 4393/4885
US-10238637-B2 Modulators of the adenosine A3 receptors ADORA3, ADORA2A, ADORA1 ALDH1A1 483/4885MAPT 3832/4885CYP1A2 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.